Prenetics Global : Investor Presentation (26 June 2023)
June 25, 2023 at 08:45 pm
Share
Saving Lives Through the Power of Early Detection
Disclaimer
2
Presentation Participants
Dennis Lo
Danny Yeung
Chairman of the Board & Co-Founder
CEO
3
Prenetics and Globally Renowned Scientist Prof. Dennis Lo Establish US$200m Joint Venture for Breakthrough Multi-Cancer Early Detection
World Class Science and IPs, led by Professor Dennis Lo, one of the
world's most influential and highly respected pioneers in liquid biopsy,
considered the father of
Non-Invasive Prenatal Testing.
Prenetics contribution is US$100M in consideration (US$80M in cash and US$20M in Prenetics shares). Capital will be directly used to accelerate clinical trials and commercialization for the Presight test, the 1st test by Insighta.
Strong and proven management team led by Prenetics
CEO - Danny Yeung. Demonstrated history of success.
4
Led by Renowned Scientist Prof. Dennis Lo, the Father of Non-Invasive Prenatal Testing (NIPT)
5
Prof. Dennis Lo
Associate Dean (Research) of the Faculty of Medicine of CUHK
Director of the Li Ka Shing Institute of Health Sciences, the Li Ka Shing Professor of Medicine and Professor of Chemical Pathology of CUHK
Founding Scientific Director of Centre for Novostics, funded by the InnoHK Initiative of the Innovation and Technology Commission of the Hong Kong SAR Government
Introduced ground breaking NIPT technology in 2011, now screening over 10 million expectant mothers annually across 90+ countries.
Global market value of NIPT stands at US$7.3bn, increasing to US$13.1bn by 2027.1
Honored with life sciences most prestigious awards: Fellow of the Royal Society (2011), Royal Medal and Breakthrough Prize (2021), and the distinguished Lasker Award (2022).
Co-foundedCirina, acquired by GRAIL for US$300m in 2017, subsequently purchased by Illumina for US$7.1bn.
Provided intellectual property, R&D leadership, and science oversight for the breakthrough multi-cancer early detection technology "Fragma," published in 20222.
Prenetics Global Ltd. published this content on 26 June 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 June 2023 00:44:08 UTC.
Prenetics Global Ltd is a company mainly engaged in the diagnostics and genetic testing business. The Company operates its business through two segments. The Diagnostics segment is engaged in the provision of COVID-19 testing services and operation testing laboratories. The Segment is also engaged in the development of health monitoring systems. The Prevention segment is engaged in the provision of genetics testing services to individuals and corporate entities.
PRENETICS GLOBAL LIMITED 
